Statements (39)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2005
gptkb:FDA |
| gptkbp:atccode |
L01 XE05
|
| gptkbp:brand |
gptkb:Nexavar
|
| gptkbp:casnumber |
475207-57-5
|
| gptkbp:chemical_formula |
C21 H16 Cl F2 N4 O3 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
pregnancy
breastfeeding severe hepatic impairment |
| gptkbp:developed_by |
gptkb:Bayer_AG
|
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
sorafenib tosylate tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
sorafenib tosylate
|
| gptkbp:indication |
differentiated thyroid carcinoma
advanced hepatocellular carcinoma advanced renal cell carcinoma |
| gptkbp:interacts_with |
gptkb:warfarin
anticoagulants CYP3 A4 inducers CYP3 A4 inhibitors |
| gptkbp:marketed_as |
gptkb:Nexavar
|
| gptkbp:mechanism_of_action |
inhibitor of multiple kinases
|
| gptkbp:pharmacokinetics |
metabolized by liver
bioavailability 38% half-life 25-48 hours |
| gptkbp:side_effect |
fatigue
nausea hypertension diarrhea rash |
| gptkbp:used_for |
treatment of thyroid cancer
treatment of kidney cancer treatment of liver cancer |
| gptkbp:bfsParent |
gptkb:Nexavar
|
| gptkbp:bfsLayer |
7
|